AI Article Synopsis
- mRNA vaccine technology has seen significant advancements, particularly with the authorization of COVID-19 vaccines, utilizing nano-scale biomaterials as delivery platforms.
- The impact of these mRNA nanoplatforms on immune responses is still not fully understood, prompting a review of their effects on both innate and adaptive immunity.
- Additionally, while mRNA vaccines have inherent adjuvant properties, the use of supplemental adjuvants may be necessary to better regulate immune responses.
Article Abstract
mRNA-based vaccine technology has been significantly developed and enhanced, particularly highlighted by the authorization of mRNA vaccines for addressing the COVID-19 pandemic. Various biomaterials are developed in nano-scales and applied as mRNA vaccine delivery platforms. However, how these mRNA nanoplatforms influence immune responses has not been thoroughly studied. Hence, we have reviewed the current understanding of various mRNA vaccine platforms. We discussed the possible pathways through which these platforms moderate the host's innate immunity and contribute to the development of adaptive immunity. We shed light on their development in reducing biotoxicity and enhancing antigen delivery efficiency. Beyond the built-in adjuvanticity of mRNA vaccines, we propose that supplementary adjuvants may be required to fine-tune and precisely control innate immunity and subsequent adaptive immune responses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10820759 | PMC |
| http://dx.doi.org/10.3390/v16010120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!